Mechanism of action and future perspectives of ADCs in combination with immune checkpoint inhibitors for solid tumors.

Clin Exp Med · 2025 · PMC12050234 · PMID 40319436

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In addition, in the Morpheus-TNBC trial, SG in combination with Atezolizumab showed a trend toward benefit (12.2 vs 5.9 m) despite immature PFS data [ 53 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.